Specifically, circulating B cells from patients with MS produce more proinflammatory (IL-6, TNF, GM-CSF) and fewer antiinflammatory (IL-10) cytokines (7), and induction of B cells that enhance IL-10 production have been thought to have potential for clinical application (8–10). The gene discussed is IL10; the disease is myeloid sarcoma.